subscribeSubscribe
price-trendAsk Us
RedHill Biopharma Announces $36 M Strategic Investment by Cosmo Pharmaceuticals

RedHill Biopharma Announces $36 M Strategic Investment by Cosmo Pharmaceuticals
BIOSPACE
19 Oct 2019
Share Share
2018 Drug Approvals: A Closer Look

2018 Drug Approvals: A Closer Look
Derek Lowe SCIENCE MAG BLOG
05 Feb 2019
Share Share
Cosmo to give Bausch Health a run for its money with FDA nod for Xifaxan rival

Cosmo to give Bausch Health a run for its money with FDA nod for Xifaxan rival
Angus Liu FIERCE PHARMA
21 Nov 2018
Share Share
FDA approves new drug to treat travelers’ diarrhea

FDA approves new drug to treat travelers’ diarrhea
FDA
17 Nov 2018
Share Share
FDA accepts NDA for Aemcolo (Rifamycin SV MMX®) and sets PDUFA Date

FDA accepts NDA for Aemcolo (Rifamycin SV MMX®) and sets PDUFA Date
PR NEWSWIRE
21 May 2018
Share Share
Valeant: A Rifamycin Threat Could Be Devastating

Valeant: A Rifamycin Threat Could Be Devastating
SEEKINGALPHA
23 Mar 2018
Share Share
Valeant partner Cosmo turns wannabe IBS-D rival, and it could do some sales damage: analyst

Valeant partner Cosmo turns wannabe IBS-D rival, and it could do some sales damage: analyst
Carly Helfand FIERCE PHARMA
29 Jan 2018
Share Share
Anvisa Suspends Two EMS Drugs

Anvisa Suspends Two EMS Drugs
ANVISA
04 Feb 2015
Share Share